InvestorQ : What is the difference between the COVID-19 permissions that Glenmark has got compared to what Cipla and Jubilant have received?
Ria Jain made post

What is the difference between the COVID-19 permissions that Glenmark has got compared to what Cipla and Jubilant have received?

Answer
user profile image
Anu Biswas answered.
3 months ago


Glenmark has received approval to manufacture and sell oral antiviral drug Favipiravir for treating mild-to-moderate COVID-19 infections. This is in contrast to the approval given to Jubilant Life and Cipla to make and market Remdesivir, a product of Gilead Inc. The drug is specially approved under restricted emergency use.

Favipiravir is owned by Japan’s Fujifilm Holdings which makes Favipiravir under the brand name Avigan. This drug is also undergoing trials in other countries to test its efficacy as a COVID-19 treatment. India is already the fourth-worst hit country and has been reporting record jump in the number of Coronavirus cases to above 12,000 per day.


user profile image
3 months ago


Pharmaceuticals giant Glenmark produced COVID drug for patients with mild cases. The market price of each tablet is Rs 103 and it will be available as a prescription drug.

Glenmark Pharmaceuticals will also manufacture and market oral antiviral drug, favipiravir in India. The drug for patients with mild to moderate symptoms and infection and it will be available as a prescription drug.

Sujesh Vasudevan, the president of Indian formulations the Middle East and Africa, Glenmark said the manufacturing process of the drug will be undertaken in the company's Baddi facility at Himanchal. The firm will also make active pharmaceutical ingredients for the drug. Also, the company is striving hard to facilitate supply across the country.